Benzinga | Feb 23, 2021 04:08PM EST

Adamas Pharmaceuticals Sees FY 2021 Total Operating Expenses Expenses $115M-$130M

Full year 2021 expense guidance

For full year 2021, Adamas estimates R&D, SG&A and stock-based compensation expenses as set forth below:

Full Year 2021

R&D expenses $5 million -- $10 million1

SG&A expenses $110 million -- $120 million2

Total operating expenses $115 million -- $130 million3

1Includes stock-based compensation expense of $1 million.

2Includes stock-based compensation expense of $8 million.

3Includes stock-based compensation expense of $9 million.